Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Drug

FDA Waskyra WAS Gene Therapy First Cell-Based

Fineline Cube Dec 10, 2025

The US Food and Drug Administration (FDA) approved Waskyra (etuvetidigene autotemcel) as the first cell‑based...

Company Drug

FDA Omisirge Severe Aplastic Anemia First HSCT

Fineline Cube Dec 10, 2025

The US Food and Drug Administration (FDA) approved Omisirge (omidubicel-onlv) as the first hematopoietic stem...

Company Deals

Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development

Fineline Cube Dec 10, 2025

Beijing Cygenta Biotech Co., Ltd. and Beijing Horicin Biotechnology Co., Ltd. announced a strategic partnership...

Company Deals

Lee’s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership

Fineline Cube Dec 10, 2025

Lee’s Pharmaceutical Holdings Limited (HKG: 0950) announced that its wholly‑owned subsidiary Nova Pneuma Inc. (NPI)...

Company Deals

Zhaoke BRIMOCHOL-PF Taiwan License Targets Presbyopia Market

Fineline Cube Dec 9, 2025

Zhaoke Ophthalmology (HKG: 6622) announced it has granted TSH Biopharm (TW-8432) exclusive rights to register,...

Company Drug

Kexing GB10 nAMD Injection Secures NMPA Clinical Trial Approval

Fineline Cube Dec 9, 2025

Kexing Biopharm (SHA: 688136) announced that its GB10 injection has received approval from China’s National...

Company Drug

Ignis Therapeutics Cenobamate NMPA Approval Targets Epilepsy

Fineline Cube Dec 9, 2025

Ignis Therapeutics announced that cenobamate tablets received marketing approval from China’s National Medical Products Administration...

Company Drug

Ignis Therapeutics Solriamfetol NMPA Approval Targets OSA Sleepiness

Fineline Cube Dec 9, 2025

Ignis Therapeutics announced that Solriamfetol Hydrochloride Tablets received approval from China’s National Medical Products Administration...

Company Drug

Abbisko ABSK043 NSCLC Combo Shows 71% Disease Control at ESMO Asia

Fineline Cube Dec 8, 2025

Abbisko Cayman Limited (HKG: 2256) announced preliminary results from the dose escalation phase of the...

Company Drug

Leads Biolabs LBL-034 Multiple-Myeloma ASH Data Shows 82% ORR

Fineline Cube Dec 8, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) reported Phase 1/2 data for LBL-034 in relapsed/refractory multiple...

Company Drug

Junshi Biosciences roconkibart psoriasis NMPA Acceptance

Fineline Cube Dec 8, 2025

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announces that the National Medical Products...

Company Drug

CSPC SYH2069 GLP-1/GIP Dual Agonist Wins FDA Nod for Obesity

Fineline Cube Dec 8, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2069 Injection, its GLP-1/GIP receptor dual-biased agonist...

Company Drug

Asieris APL-1401 Ulcerative-Colitis Phase 1b Data Positive

Fineline Cube Dec 8, 2025

Asieris Pharmaceuticals (SHA: 688176) presented Phase 1b trial data for APL-1401 in moderate-to-severe active ulcerative...

Company Medical Device

Balance Medical ePTFE Pericardial-Membrane Gets NMPA Nod, Ends Import Reliance

Fineline Cube Dec 8, 2025

Beijing Balance Medical Technology Co., Ltd. (SHA: 688198) announced that its expanded polytetrafluoroethylene (ePTFE) pericardial...

Company Deals

Shanghai Pharma X842 Deal Termination with Sinorda

Fineline Cube Dec 8, 2025

Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607) announced the termination of its...

Company Drug

Weixikang Lidocaine-Tetracaine Cream NMPA Clinical Trial Approval

Fineline Cube Dec 8, 2025

Tibet Weixikang Pharmaceutical Co., Ltd. (SHA: 603676) announced that its lidocaine-tetracaine cream has received approval...

Company Drug

Anke-Biotech PA3-17 CAR-T Pediatric Indication NMPA Accepted

Fineline Cube Dec 8, 2025

Anhui Anke Biotechnology (Group) Co., Ltd. (SHE: 300009) announced that the China National Medical Products...

Company Deals Medical Device

Mirxes XtalPi AI Platform Targets Asian GI Cancers

Fineline Cube Dec 8, 2025

Mirxes Holding Company Limited (HKG: 2629) announced it has entered into a memorandum of understanding...

Company Deals Drug

Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal

Fineline Cube Dec 8, 2025

Sirnaomics Ltd. (HKG: 2257) announced a global non‑exclusive licensing agreement with ChemPartner Co., Ltd. (SHE:...

Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025

The National Healthcare Security Administration (NHSA) released the 2025 National Medical Insurance Drug List and...

Posts pagination

1 … 122 123 124 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.